Melanoma Clinical Trial
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles
Age ≥ 18 years
Able to read and speak English fluently
Capable of giving informed consent
Patient has received a complete COVID-19 vaccination series.
Reported ability to complete 20-30 minutes moderate exercise per positive response to "can you currently walk unaided for six minutes or more?".
Scheduled for first-time checkpoint blockade immunotherapy with avelumab, cemiplimab, ipilimumab, nivolumab, or pembrolizumab in the absence of other therapies (e.g. targeted therapy)
Melanoma patients (adjuvant setting)
Melanoma patients (neoadjuvant setting)
cuSCC patients (neoadjuvant setting)
Merkel cell carcinoma patients (neoadjuvant setting)
Participants may also be required to have a full COVID vaccination series; the most up-to-date best practice guidelines for research at Moffitt Cancer Center will dictate the need for such a vaccination series.
Presence of medical conditions, such as severe cardiovascular disease for which an exercise intervention may not be warranted.
Presence of major postoperative complications for which an exercise intervention may not be warranted.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Tampa Florida, 33612, United States More Info
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.